379 related articles for article (PubMed ID: 33419683)
1. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
Sylvester RJ; Rodríguez O; Hernández V; Turturica D; Bauerová L; Bruins HM; Bründl J; van der Kwast TH; Brisuda A; Rubio-Briones J; Seles M; Hentschel AE; Kusuma VRM; Huebner N; Cotte J; Mertens LS; Volanis D; Cussenot O; Subiela Henríquez JD; de la Peña E; Pisano F; Pešl M; van der Heijden AG; Herdegen S; Zlotta AR; Hacek J; Calatrava A; Mannweiler S; Bosschieter J; Ashabere D; Haitel A; Côté JF; El Sheikh S; Lunelli L; Algaba F; Alemany I; Soria F; Runneboom W; Breyer J; Nieuwenhuijzen JA; Llorente C; Molinaro L; Hulsbergen-van de Kaa CA; Evert M; Kiemeney LALM; N'Dow J; Plass K; Čapoun O; Soukup V; Dominguez-Escrig JL; Cohen D; Palou J; Gontero P; Burger M; Zigeuner R; Mostafid AH; Shariat SF; Rouprêt M; Compérat EM; Babjuk M; van Rhijn BWG
Eur Urol; 2021 Apr; 79(4):480-488. PubMed ID: 33419683
[TBL] [Abstract][Full Text] [Related]
2. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
[TBL] [Abstract][Full Text] [Related]
3. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
[TBL] [Abstract][Full Text] [Related]
4. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
[TBL] [Abstract][Full Text] [Related]
5. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM
Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986
[TBL] [Abstract][Full Text] [Related]
6. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study.
van Rhijn BWG; Hentschel AE; Bründl J; Compérat EM; Hernández V; Čapoun O; Bruins HM; Cohen D; Rouprêt M; Shariat SF; Mostafid AH; Zigeuner R; Dominguez-Escrig JL; Burger M; Soukup V; Gontero P; Palou J; van der Kwast TH; Babjuk M; Sylvester RJ;
Eur Urol Oncol; 2021 Apr; 4(2):182-191. PubMed ID: 33423944
[TBL] [Abstract][Full Text] [Related]
8. Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum.
Beijert IJ; Hentschel AE; Bründl J; Compérat EM; Plass K; Rodríguez O; Subiela Henríquez JD; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Claps F; Masson-Lecomte A; Liedberg F; Cohen D; Lunelli L; Cussenot O; El Sheikh S; Volanis D; Côté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Ribal MJ; van der Kwast TH; Babjuk M; Sylvester RJ; van Rhijn BWG
Eur Urol Oncol; 2023 Apr; 6(2):214-221. PubMed ID: 36670042
[TBL] [Abstract][Full Text] [Related]
9. External validation of European Association of Urology NMIBC risk scores to predict progression after transurethral resection of bladder tumor in Korean patients with non-muscle-invasive bladder cancer.
Kim JY; Lee DB; Song WH; Lee SS; Park SW; Nam JK
Investig Clin Urol; 2022 Sep; 63(5):531-538. PubMed ID: 36067998
[TBL] [Abstract][Full Text] [Related]
10. Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey.
Hendricksen K; Aziz A; Bes P; Chun FK; Dobruch J; Kluth LA; Gontero P; Necchi A; Noon AP; van Rhijn BWG; Rink M; Roghmann F; Rouprêt M; Seiler R; Shariat SF; Qvick B; Babjuk M; Xylinas E;
Eur Urol Focus; 2019 Jul; 5(4):681-688. PubMed ID: 29074050
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
Soukup V; Čapoun O; Cohen D; Hernández V; Babjuk M; Burger M; Compérat E; Gontero P; Lam T; MacLennan S; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R
Eur Urol; 2017 Nov; 72(5):801-813. PubMed ID: 28457661
[TBL] [Abstract][Full Text] [Related]
12. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.
Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
Eur Urol; 2011 Jun; 59(6):997-1008. PubMed ID: 21458150
[TBL] [Abstract][Full Text] [Related]
13. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG.
Contieri R; Hurle R; Paciotti M; Casale P; Saita A; Porpiglia F; Fiori C; Barone B; Crocetto F; Lucarelli G; Busetto GM; Del Giudice F; Maggi M; Cantiello F; Damiano R; Borghesi M; Bove P; Bertolo R; Papalia R; Mari A; Luzzago S; Mistretta FA; Soria F; Gontero P; Marchioni M; LA Civita E; Terracciano D; Russo GI; Schips L; Perdona S; Mirone V; Tataru OS; Musi G; Vartolomei MD; Autorino R; Montanari E; DE Cobelli O; Ferro M
Minerva Urol Nephrol; 2023 Apr; 75(2):180-187. PubMed ID: 36197700
[TBL] [Abstract][Full Text] [Related]
15. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
[TBL] [Abstract][Full Text] [Related]
16. Impact of an optimized surveillance protocol based on the European Association of Urology substratification on surveillance costs in patients with primary high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Okita K; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
PLoS One; 2023; 18(2):e0275921. PubMed ID: 36763567
[TBL] [Abstract][Full Text] [Related]
17. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
[TBL] [Abstract][Full Text] [Related]
18. International Opinions on Grading of Urothelial Carcinoma: A Survey Among European Association of Urology and International Society of Urological Pathology Members.
Beijert IJ; Cheng L; Liedberg F; Plass K; Williamson SR; Gontero P; Ribal MJ; Babjuk M; Black PC; Kamat AM; Algaba F; Berman DM; Hartmann A; Masson-Lecomte A; Rouprêt M; Lopez-Beltran A; Samaratunga H; Shariat SF; Mostafid AH; Varma M; Shen S; Burger M; Tsuzuki T; Palou J; Compérat EM; Sylvester RJ; van der Kwast TH; van Rhijn BWG; Downes MR
Eur Urol Open Sci; 2023 Jun; 52():154-165. PubMed ID: 37284047
[TBL] [Abstract][Full Text] [Related]
19. [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update].
Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
Actas Urol Esp; 2012; 36(7):389-402. PubMed ID: 22386115
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer.
Magalhães JC; Sousa M; Basto R; Fraga T; Gomes I; Fernandes C; Mariano M; Paulo J; Madeira P; Sousa G
Cureus; 2023 Sep; 15(9):e45672. PubMed ID: 37745737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
